GX-E4 (anemia): Approved in Indonesia and Cambodia, domestic filing expected Q2 2026; phase 3 for dialysis patients ongoing in multiple countries including Europe.
GX-I7 (immuno-oncology): Phase 2 completed in recurrent glioblastoma; phase 1b/2 completed in triple-negative breast cancer.
GX-188E (HPV DNA vaccine): Final CSR for phase 1b/2 in cervical cancer completed; investigator-initiated phase 2 for head and neck cancer ongoing.
GX-H9 (growth hormone): Phase 3 in pediatric patients in China completed; preparing for BLA resubmission.
bioPROTAC platform: Early-stage pipeline with 10+ targets identified.
Merger with EPD Biotherapeutics provides targeted protein degradation technology.